Figure S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Stéphane Fattori; Laurent Gorvel; Marie-Sarah Rouvière; Samuel Granjeaud; Amira Ben Amara; Manon Richaud; Nicolas Boucherit; Carole Tarpin; Jihane Pakradouni; Julien Hédou; Grégoire Bellan; Brice Gaudillière; Emmanuelle Charafe‐Jauffret; Gilles Houvenaeghel; Éric Lambaudie; François Bertucci; Jean‐Jacques Fournié; Anthony Gonçalvès; Philippe Rochigneux; Anne-Sophie Chrétien; Daniel Olive

doi:10.1158/2326-6066.30255232

Implication

Observational analysis shows vg9vd2 t cells enhance responses to anti–pd-l1 therapy in triple-negative breast cancer, indicating potential treatment avenues.

Abstract

Vg9Vd2 T cells are associated with better clinical responses to PD–(L)1 blockade therapy (related to Figure 5).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fattori et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a93 https://doi.org/10.1158/2326-6066.30255232

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows vg9vd2 t cells enhance responses to anti–pd-l1 therapy in triple-negative breast cancer, indicating potential treatment avenues.

Abstract

Vg9Vd2 T cells are associated with better clinical responses to PD–(L)1 blockade therapy (related to Figure 5).

Figure S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Implication

Abstract

Discussion

Cite This Study

Figure S9 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers